MXPA05005314A - Compuestos de lapacona novedosos y metodos de uso de los mismos. - Google Patents

Compuestos de lapacona novedosos y metodos de uso de los mismos.

Info

Publication number
MXPA05005314A
MXPA05005314A MXPA05005314A MXPA05005314A MXPA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A
Authority
MX
Mexico
Prior art keywords
methods
compounds
lapachone compounds
novel
prevention
Prior art date
Application number
MXPA05005314A
Other languages
English (en)
Spanish (es)
Inventor
Zhiwei Jiang
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MXPA05005314A publication Critical patent/MXPA05005314A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MXPA05005314A 2002-11-18 2003-11-18 Compuestos de lapacona novedosos y metodos de uso de los mismos. MXPA05005314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MXPA05005314A true MXPA05005314A (es) 2005-10-19

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005314A MXPA05005314A (es) 2002-11-18 2003-11-18 Compuestos de lapacona novedosos y metodos de uso de los mismos.

Country Status (12)

Country Link
US (1) US20040266857A1 (OSRAM)
EP (1) EP1567515A4 (OSRAM)
JP (1) JP2006508147A (OSRAM)
CN (1) CN1729183A (OSRAM)
AR (1) AR056613A1 (OSRAM)
AU (1) AU2003295738A1 (OSRAM)
BR (1) BR0316296A (OSRAM)
CA (1) CA2506340A1 (OSRAM)
EA (1) EA200500849A1 (OSRAM)
MX (1) MXPA05005314A (OSRAM)
TW (1) TW200510367A (OSRAM)
WO (1) WO2004045557A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
CA2546445A1 (en) 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082359A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2555941A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
JP2007523191A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 血液腫瘍の治療のためのβ−ラパコンの使用
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
JP2007523192A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 広域スペクトラム抗癌剤としてのβ−ラパコンの使用
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2583700A1 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
EP1836320A2 (en) 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2007139569A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2137168B1 (en) * 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
MX2009011822A (es) 2007-04-30 2010-01-14 Arqule Inc Hidroxi sulfonatos de compuestos de quinonicos y sus usos.
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
EP2575740A4 (en) * 2010-06-01 2015-09-30 Belle Aire Fragrances Inc METHOD AND PRODUCT FOR COMBATTING ORAL ODORS
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
JP2005538981A (ja) * 2002-07-17 2005-12-22 アーキュル, インコーポレイテッド 活性化チェックポイント療法およびこれらの使用方法

Also Published As

Publication number Publication date
EP1567515A4 (en) 2008-04-23
CN1729183A (zh) 2006-02-01
AU2003295738A1 (en) 2004-06-15
AR056613A1 (es) 2007-10-17
WO2004045557A2 (en) 2004-06-03
JP2006508147A (ja) 2006-03-09
WO2004045557A3 (en) 2004-08-12
EA200500849A1 (ru) 2006-02-24
BR0316296A (pt) 2005-12-13
CA2506340A1 (en) 2004-06-03
EP1567515A2 (en) 2005-08-31
TW200510367A (en) 2005-03-16
US20040266857A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
IL260127B (en) mek inhibitors and methods of using them
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
PH12012501372B1 (en) Proteasome inhibitors and methods of using the same
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
MY162518A (en) Proteasome inhibitors and methods of using the same
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
GB0407025D0 (en) Novel compounds
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN
UA96742C2 (en) Mek inhibitors and use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal